



Psychiatr Clin N Am
26 (2003) 1017–1047

PSYCHIATRIC
CLINICS OF
NORTH AMERICA

Cumulative Index 2003

Volume 26

March	SCHIZOPHRENIA: CONTEMPORARY CLINICAL PERSPECTIVES. pages 1–302
June	DRUG THERAPY: PREDICTORS OF RESPONSE, pages 303–528
September	WOMEN'S MENTAL HEALTH, pages 529–810
December	EVIDENCE-BASED PRACTICES IN MENTAL HEALTH CARE, pages 811–1047

Note: Page numbers of article titles are in **boldface** type.

A

- Acamprosate, response prediction for, in alcoholism, 390
- Addiction treatment services, for substance use disorders, 1002
- Addictive disorders, simple phobia and, 639
- Addison's disease, psychiatric symptoms in, 687
- Administrators, concerns about evidence-based practice, continuous training needs and limited training capacities, 929–930
- displacement of services of established provider groups, 929
 - investment cost for cost-effective implementation, 928–929
- Adolescents, automated self-report and, 840
- Affective disorders, in children and adolescents, family functioning and interaction styles and, as response predictor, 440–441
- parental, depression in children and, 441
- Affective illness, response prediction studies, calculation of power a priori, 338
- reporting practical statistics, 338
 - importance in, of homogeneous groups, 337
 - of well-controlled studies, 337
 - utilization of all versus specified data, 337–338
- response predictors in, electroencephalograms, 329–330
- endocrine studies, 326–328
- event-related potentials and, 328–329
- imaging studies, 330–336
- neuroendocrine studies, 324–328
- neurotransmitters and metabolite levels and, 324–325
- structural imaging, 330–333
- Age, as response predictor, to antidepressants, 357
- Age discrimination, women and, 753
- Aggression. *See also Violence* of psychotic patient.
- nonpharmacologic management of, 239–242
 - behavioral, 240–241
 - restraint, 241–244
 - seclusion, 241–244
 - treatment setting in, 239–230
 - pharmacologic management of, 242–251
- Agoraphobia, in panic disorder, 629–630, 633–634
- social anxiety disorder and, 644–645
- Alcoholism, anxiety in, 389
- biologic markers for, 382–385
 - cognitive functions in, 386
 - cravings and urges in, 386
 - cue reactivity in, biologic markers of, 384–385
 - depression in, 388–389
 - dopamine system in, 382–383
 - dopamine D2 allele in, 383
 - electroencephalogram in, 384
 - expressed emotions of spouse and family, outcome prediction and, 388

Alcoholism (continued)

- genetic and environmental causes of, 385
 - neurotransmitters, neuromodulators, postsynaptic processes and, 383
 - opioid deficiency hypothesis for, 383
 - opioids and, endogenous, 383
 - personality factors in, 387-388
 - pharmacotherapy for, response predictors in, 389-390
 - psychiatric comorbidity in, outcome and, 388-389
 - psychological predictors of, 386-390
 - rapid eyemovement sleep and, 384
 - self-efficacy, as positive response predictor, 388
 - serotonin and, 383
 - sleep disturbances and, 384
 - stress and, 386-387
 - typology of, 385
- Alcohol use/abuse, comorbid, with bipolar disorder, 600**
- with panic disorder in women, 633
 - geriatric, treatment of, 981
 - in geriatric mental health care, 981
 - in geriatric population, pharmacologic and psychosocial treatments for, 981
 - pharmacotherapies for, 996-998
- Alzheimer's disease, APO E genotype in, as response predictor, 314**
- American Psychological Association, clinical psychology division, evidence-based practice and, for substance use disorders, 994-995**
- criteria for established efficacious interventions, in childhood, 955-956
- Amisulpride, in acute schizophrenia, versus conventional antipsychotics, 147**
- versus haloperidol, 147
 - versus placebo, 143-144
- in schizophrenia, for maintenance treatment, 150
- for negative symptoms, 152
- Androgens, premenstrual dysphoric disorder and, 532-533**
- Anger, coronary events and, 698**
- Antabuse. See Disulfiram (Antabuse)**
- Antenatal depression. See Depression, during pregnancy**
- Anticonvulsants, teratogenic effects of, 606**
- Antidepressants, in atypical depression, positive response in, 350**
- in bipolar disorder, controversies regarding, 507

- in combination with neuroleptics, for psychotic depression, positive response to, 350
- in complex posttraumatic stress disorder, 772
- in generalized anxiety disorder, gender differences in, 627-628
- in geriatric depression, 973-975
- in menopause, for depression, 571-572
- in pregnancy, risks with, 550-555
 - neonatal toxicity, 553-554
 - neurobehavioral effects on fetus, 555
 - spontaneous abortion, 551
 - teratogenesis, 551-553
- response predictors for, **345-352**.
See also *Response prediction*.
- response to, age and gender and, 589-590
 - in anxiety disorders, in children and adolescents, 446
 - exogenous estrogen and, in postmenopausal women, 590
 - gender differences in, **581-594**, 587-590
- in schizophrenia, for negative symptoms, 944
- selection principles and, 467-468
- switching, to bupropion, 468
 - to mirtazapine, 469
 - to monoamine oxidase inhibitors, 469
 - from selective serotonin reuptake inhibitors to TCAs, 468
 - within selective serotonin reuptake inhibitor class, 468
 - to vortioxetine, 468-469

- Antipsychotic medications, extrapyramidal effects of, 941**
- first generation, efficacy of, 940-941
 - introduction of, 868-869
 - in schizophrenia, for cognitive impairments, 947
 - for negative symptoms, 944
 - for positive symptoms and relapse, 940-942
 - second generation, tolerability and safety of, 941, 942
 - traditional, response to, 942
- Antipsychotics. See also Atypical antipsychotics**
- history of, 191-192
 - in schizophrenia, acute phase, 217
 - comorbid with substance abuse, 122
 - late-onset, 106-108
 - time to remission with, 221
 - time to response with, 221

- typical, hyperprolactinemia with, 603-604
- weight gain, diabetes, dyslipidemia triad with, 165-175
- Antisocial personality disorder, as outcome predictor, in cocaine dependence, 395
- Anxiety, in alcoholism, 389
- automated self-report in, 939
- cardiac disease and, 701
- chemotherapy-related, in women with breast cancer, 717-718
- and outcome, of opioid detoxification, 396
- premenstrual, 605
- in premenstrual syndrome, 535
- sudden cardiac death and, 701
- Anxiety disorder(s), adverse consequences of, 623
- comorbidity in, in children and adolescents, response prediction in, 445-446
- comorbid with bipolar disorder, 600-601
- DSM-IV classification of, 621
- generalized anxiety disorder, 624-628
- generalized anxiety disorder, 412-416
- in geriatric mental health care, 982-983
- lifetime prevalence rate for, 621-622
- major depressive disorder risk in, gender and, 622-623
- obsessive-compulsive disorder, 421-429
- obsessive-compulsive disorder, 646-652
- in older persons, treatment of, 982-983
- panic disorder, 629-639
- in women, 632-635
- posttraumatic stress disorder, 418-421, 652-657
- response predictors in, 411-433
- simple phobia, 639-640
- social anxiety disorder, 416-418, 640-645
- in women, 621-671, 786
- with cardiac disease, 700-702
- factors in, 623-624
- prevalence of, U.S. and worldwide, 622
- Anxiety symptoms, in women, cardiac rehabilitation and, 697
- Anxiolytics, for premenstrual dysphoric disorder, 539
- Arachadonic acid (AA). See *Essential polyunsaturated fatty acids (EPUFAs)*
- Aripiprazole, comparison with risperidone or olanzapine, in schizophrenia, 370
- Assertive community training (ACT), for patients with schizophrenia, 206-207
- Assertive community treatment, Program of Assertive Community Treatment, for schizophrenia, positive symptom reduction and relapse, 943
- Association studies, in schizophrenia, 50-51
- catechol-*O*-methyltransferase and, 51-52
- classic markers in, 51
- genes in neurodevelopmental process and, 52
- interpretation of, 52
- serotonergic neurotransmission and, 51
- Attachment, adjustment to trauma and, 767
- Attention, in schizophrenia, 29
- sustained, in schizophrenia, 33
- Atypical antidepressants, adverse effects of, metabolic, 373-374
- cost effectiveness of, in schizophrenia, 374-375
- limitations of, 373
- Atypical antipsychotics. See also *Antipsychotics*
- in acute psychotic episodes, limitation of, 371
- adverse effects of, 371
- in bipolar disorder, 9
- comparison with haloperidol, in schizophrenia, acute psychotic, 370
- in schizophrenia, 9
- acute phase, 216-217
- adverse effects of, dyslipidemias, 170-173
- glucose metabolism abnormalities, 169-170
- hyperprolactinemia, 178-181
- Q-T segment prolongation, 175-178
- sexual, 181-184
- weight gain, 165-169
- for cognitive deficits, 34-36
- late-onset, 108-111
- mechanism of action of, on cognitive deficits, 35-36
- in substance abuse-schizophrenia comorbidity, 122
- versus typical antipsychotics, cost effectiveness of, 374-375
- reduction of rehospitalization, 374-375
- versus typical neuroleptics, 368-369
- Auditory event-related brain potentials, as response predictors, in antidepressant therapy, 359

- Auditory evoked potentials, response to serotonergic antagonists and, 358
- Augmentation studies, for major depressive disorder, 464-465
- Automated clinical treatment (ACT) systems, 844
- Automated self-report (ASR), adult patient and, acceptance of, 841-842
- diagnostic, child-structured, 840-841
- integrated, 836-837
- screening interviews, 837-838
- self-disclosure on, 842
- severity rating systems and, 838-842
- for obsessive-compulsive disorder, 839-840
- Avoidant personality disorder, social anxiety disorder and, 643

B

Behavioral couples therapy, 999

- Benzodiazepines, for aggressive patient with schizophrenia, 250
- in generalized anxiety disorder, in women, 628
- in panic disorder, 631, 637
- in social anxiety disorder, 644

- Beta-blockers, for aggressive patient with schizophrenia, 250

- Bipolar disorder (BPD), in children and adolescents, consequences of, 438
- diagnostic difficulty in, 437-438
- prognosis in, 438
- psychotic features in, response to treatment and, 444
- relapse in, 438
- response predictors in, age, 439
- demographic, 438-440
- family environment, 440-442
- gender and, 438-439
- psychosocial, 440-442
- referral source, 439
- subtypes of, as response predictors, 444-445
- symptom presentation in, 443-444
- comorbidity in, in children and adolescents, response to lithium in, 447
- comparison with schizophrenia, 2-10, 14
- causes of, 6
- characterization in, 3-4
- cognitive performance in, 3
- demographics in, 4-5
- epidemiology in, 5-6

- neuropathology in, 6-7
- overlapping issues in, 9-10
- pathophysiology in, 10
- treatment response in, 8-9
- depression in, 495-496
- gender differences in, **595-620**
- age of onset and, 595
- comorbidity and, 599-601
- depressive episodes and, 596
- mixed mania and, 598-599
- psychiatric comorbidity in, 600-601
- psychosocial outcome and, 601
- rapid cycling and, 596-598
- seasonal changes and, 595-596
- suicidality and, 601-602
- treatment and, 603-604
- parental, mood disorder in children and, 441
- psychological interventions in, cognitive behavioral therapy, 513
- family therapy, 514
- goals of, 512-513
- interpersonal and social rhythms therapy, 513
- psychotherapy and STEP-BD, 514
- reproductive cycle and, 604-610
- lactation in, 608-609
- menopause in, 609-610
- menstrual cycle in, 604-605
- postpartum in, 607-608
- pregnancy in, 605-607
- social anxiety disorder and, 642
- STEP-BD approach in, **495-518**
- acute phase therapy, 499-507
- antidepressant therapy in, controversies in, 507
- break-through depressive episodes, 507-510
- bupropion in, 508, 510
- carbamazepine in, 506
- citolapram in, 509-510
- divalproex sodium in, 503-505
- expert practice guidelines in, 496-499
- gabapentin in, 506
- lamotrigine in, 501-503
- lithium in, 501, 507-508
- long-term therapy in, with antidepressants, 511-512
- moclobemide in, 511
- monoamine oxidase inhibitors in, 510-511
- mood stabilizer monotherapy in, 496, 500-507
- olanzapine in, 505-506
- paroxetine in, 508-509
- psychological interventions in, 512-514

- selective serotonin reuptake inhibitors in, 508-510
- topiramate in, 506
- tranylecypromine in, 510-511
- venlafaxine in, 510
- in women, 287
 - evaluation of, 610
 - with obsessive-compulsive disorder, 650
 - risk factors for, 787
 - treatment implications for, 787
- Bipolar II disorder, comparison with bipolar I disorder, 602
- gender differences in, 602-603
- rapid cycling and, 596-597
- pharmacotherapy for, 602-603
- rapid cycling in, 596-597
- Bone marrow transplantation, in women with breast cancer, 719
- Boundaries, of schizophrenia, 1-24
- Brain, neuropathology of, in schizophrenia and bipolar disorder, 6-8
- Breast cancer, psychiatric aspects of, 713-724
 - in women, adjuvant chemotherapy for, 717-718
 - advanced disease, 719-720
 - biopsychosocial impact of, 715-716
 - bone marrow transplantation for, 719
 - early detection and decision making and, 714-715
 - family and, 721
 - hormonal therapy for, 718-719
 - incidence of, 713
 - lumpectomy and radiation therapy, 717
 - management of distress in, 716
 - mastectomy for, 716-717
 - medical factors in, 716
 - metastatic, treatment of, 719-720
 - psychiatric consultation in, 715-716, 720
 - psychosocial intervention in, 720
 - treatment of, physiologic or psychosocial disability from, 721-722
- Brief interventions, for substance use disorders, 999
- Brief strategic family therapy (BSFT), for substance use disorders, 1000
- Buprenorphine, in opioid use disorders, 998
- Bupropion, fetal exposure to, 553
- Bupropion (BUP), in break-through depression, 510
- response to, in typical versus atypical depression, 355
- with selective serotonin reuptake inhibitors, in treatment-resistant depression, 467
- Burden, definitions of, 782
- of mental illness, in women, 781-782
- Buspiron (BUS), augmentation, in treatment-resistant depression, 466
- C**
- Calcium supplementation, for premenstrual dysphoric disorder, 537
- Candidate genes, in pharmacogenomics, 306-307
 - studies of clozapine response, 309-310
 - in pharmacogenomic studies of clozapine response, 309-310
 - and polymorphisms, in pharmacogenomics, 306-307
- Carbamazepine, in bipolar disorder, 506
- response to, in mixed mania, 599
- serum concentration, in nursing infants, 609
- Cardiovascular disease, in women, cardiac rehabilitation and, 696
 - cardiac transplantation and, 695-696
 - coronary revascularization and, 694-695
 - demographics of, 693-694
 - depression and anxiety and, 700-701
 - education and employment and, 699-700
 - mental health issues in, 693-712
 - myocardial infarction mortality and, 694
 - psychosocial factors in, 698-702
 - social support and, 699
 - type A personality and, 698
- Care pathway, quality care and, 222-223
- Catechol-O-methyltransferase, in schizophrenia, gene coding for, 51-52, 115
- Catechol O-methyltransferase (COMT), dopamine metabolism and, 312
- genetic forms of, 306, 312
- Center for Mental Health Services (CMHS), administration of block grant, 915
- Children's Services Grant Program of, evidence-based practice in, 961

(CMHS) (continued)

- collaboration with NIMH in planning, fielding, evaluating demonstration programs, 912
- Character dimensions, as response predictor, to antidepressants, 361
- Childhood abuse, anxiety disorders and, 623-624
- Childhood sexual abuse, effects of, 761
 - posttraumatic stress disorder and, 655
 - premenstrual syndrome/premenstrual dysphoric disorder and, 535-536
 - prevalence of, 760
- Childhood trauma, disturbances following, 760-761
- Children, automated self-report and, 840-841
 - evidence-based practice and, 955-969
 - American Psychological Association criteria for established efficacious interventions, 955-956
 - community-based service models, 958-960
 - disorders and treatments for, 956-957
 - dissemination of, questions in, 965-966
 - family education and support, 958-959
 - future and, 962-966
 - initiatives in, 960-962
 - intensive community-based interventions, 958
 - knowledge base and, 956-960
 - MacArthur Foundation Child Mental Health Initiative and, 962
 - merger of research and practice and, 963
 - multi-systemic therapy, 958-959
 - psychopharmacology and, 957-958
 - reduction of gap between research and practice, 963
 - residential treatment and group homes, 958
 - safety in research and, 963-964
 - treatment foster care, 958-959
- Cholinesterase inhibitors, in dementia, in geriatric population, 980
- Chromosomal abnormalities, in schizophrenia, 52-53
- Chronic episodic disorder(s) (CEDs), commonalities of, 725
 - gender differences in, biologic factors in, 734-735
 - polygenetic predisposition to, 735
 - psychological factors in, 735
 - sociocultural factors in, 735
- linkage of, epidemiologic, 726-727
 - pathophysiologic, 727
 - response to treatment and, 727-728
- in women, 725-740
 - bidirectional relationship in, 726
 - comorbidity, linkage, pharmacologic response in, 725-728
 - depressive disorders and, 728-731
 - fibromyalgia, 733-734
 - irritable bowel syndrome, 732-733
 - migraine headaches, 731-732
- Cigarette smoking, in schizophrenia, 126
- Citalopram (CIT), in break-through depression, 509-510
 - in STAR*D protocol, continuation with, 482-483
 - as first-step agent, 479
- Clinic/community intervention development model, evidence-based practice and, 964-965
- Clomipramine, for premenstrual dysphoric disorder, 539
- Clonazepam, comparison with cognitive behavioral therapy, for outcome, in social phobia, 418
- Clonidine, for complex posttraumatic stress disorder, 773
- Clozapine, advantages of, 367-368
 - for aggressive patient with schizophrenia, 247-248
 - comparison with haloperidol, for cost effectiveness, 375
 - versus haloperidol, in relapse reduction, in schizophrenia, 372
 - response of, to dopamine genes, 309-310
 - in schizophrenia, for cognitive deficits, 34-36
 - for depression, 945
 - history of, 367-368
 - late-onset, 108-109
 - refractory to treatment, 156, 158, 192
 - suicide reduction and, 124
 - for violence and suicidality, 946
 - and smoking cessation, 126
 - triglyceride level increase with, 171
- Cocaine addiction, pharmacologic research in, 999

- Cocaine dependence, concurrent alcoholism and, treatment response and, 394
- outcome predictors in, baseline versus proximal, 392-393
- craving, 394-395
- drug and alcohol comorbidity, 394
- gender, 393
- psychopathology, 393-394
- psychosocial treatment
- interaction with, 392
- severity of dependence, 391-392
- Cognitive behavioral therapy, with pharmacotherapy, in schizophrenia, coping strategy enhancement in, 197-198
- for negative symptoms, 198-199
- for residual symptoms, 197
- in schizophrenia, for obsessive-compulsive symptoms, 120
- Cognitive behavioral therapy (CBT), in bipolar disorder, 513
- for children, for internalizing disorder, 61
- for complex posttraumatic stress disorder, 772
- discontinuation of antidepressant therapy and, 556-557
- for posttraumatic stress disorder, 769
- for premenstrual dysphoric disorder, 538
- response to, in children and adolescents, with major depression and comorbid anxiety, 446
- for schizophrenia, 944-945
- positive symptom reduction and relapse, 943-944
- for substance use disorders, 1000
- Cognitive deficits, in schizophrenia, antipsychotic therapies for, 34-36
- functional consequences of, 31-34
- Cognitive function, in alcoholism, treatment outcome and, 386
- characterization of, 25
- chemotherapy and, in women with breast cancer, 718
- in menopause, 572-573
- in schizophrenia, **24-40**
- attention and information processing and, 29
- contemporary understanding, 26-27
- correlation with functional outcome, 32-33
- executive function and, 28-29
- historical perspective, 26
- impaired, 31-32
- learning and memory and, 30-31
- rehabilitation outcome and, 33-34
- specific deficits in, 27-31
- working memory and, 27-28
- Cognitive remediation, for schizophrenia, 203-204
- Combination therapy, in treatment-resistant depression, 466-467
- Command hallucinations, violence and, 235
- Comorbidity, in schizophrenia, **115-139**
- depressive disorders, 116-118
- detection and management of, **115-139**
- medical, 125-130
- obsessive-compulsive symptoms, 118-120
- psychiatric, 116-124
- substance abuse, 120-123
- suicide, 123-124
- Complex posttraumatic stress disorder, nonpharmacologic treatment of, 770-771
- pharmacotherapy for, 772-773
- treatment of, staged approach to, 770-771
- Composite International Diagnostic Interview (CIDI), 836
- Consent, and pharmacogenomics, 315
- Consent to treatment, capacity for, in aggressive patient with schizophrenia, 251-252
- Consumers, concerns about evidence-based practice, 922-923
- consumers versus researchers on outcomes, 925-926
- in funding competition, will only evidence-based practice survive, 921, 924
- researchers and professions will diminish consumer power, 925
- use of treatment evidence-based practice algorithms may prevent individualized treatment, 924-925
- and families, in implementation of evidence-based practice, **867-881**
- Contingency management (CM), for substance use disorders, 1000
- Coping strategies, adjustment to trauma and, 767
- in substance dependencies, 387
- women, for role conflict or overload, 749-750

- Corticosteroids, dexamethasone suppression test and, 325-326
- Corticotropin-releasing factor (CRF), in irritable bowel syndrome, 733
- Cortisol, treatment response and, 325
- Costs, of mental illness, direct and indirect, 782
- Counseling, for substance use disorders, 1000
- Craving, as outcome predictor, in cocaine dependence, 394-395
- Cravings and urges, in alcoholism, relapse prediction and, 386
- Cushing's syndrome, psychiatric symptoms in, 686

D

- Danazol, for premenstrual syndrome/premenstrual dysphoric disorder, 539-540
- Dehydroepiandrosterone (DHEA), and response to ECT, 326
- Dehydroepiandrosterone sulfate (DHEA-S), ECT response prediction and, 360
as response predictor, to ECT, 359-360
- Deinstitutionalization, antipsychotic medications and, introduction of, 868-869
coping with basic living abd, 869-870
evidence-based practice Project and, 870-871
core interventions for outpatient setting, 870-871
family and, as case manager, 870
through National Alliance for the Mentally Ill, 871-872
mental health care system and, 868
peer support interventions and, 871, 875
- Delusions, violence and, 235-236
- Dementia, in geriatric mental health care, 977-980
pharmacologic treatments for, 978-980
psychosocial and environmental modifications in, 978-980
- Dementia praecox*, 104-105
schizophrenia and, 1-4
- Depression. See also *Major depressive disorder (MDD)*
in adolescents, cognitive distortions in, pharmacologic treatment of, 444
in alcoholism, response prediction and, 388-389, 394
automated self-report in, for major active, 839
for screening, 839
in bipolar disorder, gender differences in, 596
break-through, in bipolar disorder, 507-510
bupropion for, 510
selective serotonin reuptake inhibitors for, 508-510
venlafaxine for, 510
cardiac disease and, 701-702
chemotherapy-related, in women with breast cancer, 718
in children and adolescents, 437
diagnostic criteria for, 443
severity of, as outcome predictor, 444
in cocaine dependence, relapse and, 393-394
response to treatment and, 394
comorbid, in generalized anxiety disorder, 625
in women, 783
comorbidity in, 586, 726-727
comorbidity in, 354
epidemiology of, 581-582
gender differences in, 581, **581-594**
antidepressant treatment and, pharmacokinetics of, 586-590
response to treatment, 587-590
in clinical features of comorbidities and, 586
etiology of, 582-585
life event stress and, 583-584
neurobiologic factors in, 584-585
in prevalence, 582-585
psychosocial factors in, 584
symptoms, comorbidities, and course of illness, 585-586
in geriatric mental health care, 973-977
antidepressants for, 973-975
psychosocial treatments for, 975-976
impact of, 582
lifetime prevalence of, 581-582
major, subtypes of, 354
marijuana use and, 394
melancholic, treatment effectiveness in, 355
menopausal, 570
characteristics of, 571

- treatment strategies for, 571-572
 - migraine headaches and, in women, 731-732
 - postpartum, 785, 792
 - prediction of, with tryptophan depletion, 360
 - during pregnancy, **547-562**
 - antidepressant use and, 550-555
 - medical disorder-related, 549
 - nonpharmacologic treatment of, 550
 - relapse and, 548-549
 - risk factors for, 548
 - treatment of, 555-558
 - nonpharmacologic, 556-558
 - pharmacologic, 557-558
 - risks associated with, 556
 - untreated, risks of, 549-550
 - response prediction in, duration of treatment and, 356
 - neuroanatomic predictors, 362
 - response predictors in, biochemical, 359-361
 - clinical, 354-357
 - demographic, 357-358
 - endocrinologic, 359-361
 - physiologic, 358-359
 - risk factors for, in
 - obsessive-compulsive disorder, 650
 - in women, 784-785
 - in schizophrenia, medications for, 945
 - severity of, as predictor of response, 355-356
 - as syndrome, 354
 - in women, with breast cancer, 718, 720
 - with generalized anxiety disorder, 626-627
 - interventions and, 785
 - risk factors for, 784-785
- Depressive disorders, in schizophrenia, 116-117
 - detection of, 117-118
 - management of, 118
 - prognostic significance of, 117
- in women, 783
 - versus men, 728
 - perimenopause and menopause and, 730-731
 - postpartum, 729-730
 - premenstrual dysphoric disorder and, 729
- Depressive symptoms, in women, cardiac rehabilitation and, 697
 - with diabetes mellitus, 688
 - with hypothyroidism, 685
 - radiation therapy for breast cancer and, 717
- Dexamethasone-corticotropin-releasing hormone test, in depression, response prediction and, 359
- Dexamethasone suppression test (DST), in depression, as response predictor, 359
 - as response predictor, 359
 - in adults, 447-448
 - in children and adolescents, 447
 - for treatment response prediction, 325-326
- Diabetes, atypical antipsychotic-related, 170
 - type 2, antipsychotic medication-related, in schizophrenia, 128-130
- Diabetes mellitus, 687
 - in women, psychiatric disorders with, 688
 - sexual dysfunction with, 688
- Diagnostic Interview Schedule (DIS), 836
 - automated self-report version, 836-837
- Diagnostic Interview Schedule Screening Interview (DISSI), 837
- Diet, for premenstrual dysphoric disorder, 536-537
- Dissociation, posttraumatic stress disorder and, 764-765
- Disulfiram (Antabuse), for alcohol use disorders, 996-997
 - response prediction for, 390
 - in substance abuse-schizophrenia comorbidity, 123
- Divalproex, for bipolar disorder with migraine headaches, 599
 - response to, in bipolar disorder, rapid-cycling, 597
- Divalproex sodium, in bipolar disorder, 503-505
- Docosahexaenoic acid (DHA). See *Essential polyunsaturated fatty acids (EPUFAs)*
- Dopamine receptors, clozapine response and, 309-310
- Dyslipidemias, atypical antipsychotic-related, 170-173
- Dysthymia, social anxiety disorder and, 642
 - in women, with hypopituitarism, 684
- E**
- Eating disorders, in women, with diabetes mellitus, 688
- EBM. See *Evidence-based medicine (EBM)*

- Education, of psychiatrists, clinical
 computing in, 844-845
 PDAs in, 844-845
- Electroconvulsive therapy (ECT),
 postseizure fractal dimension in, in
 response prediction, 358
 during pregnancy, 558
- Electroencephalogram (EEG), beta
 activity in, in alcoholism, 384
 in major depressive disorder, ECT
 response and, 329-330
 multichannel, response to depression
 and, 362
 as response predictor, in children and
 adolescents, 449
- Electronic medical record (EMR), in
 psychiatry, current state of, 834-835
 potential for, 834
- Endocrine disorders, psychiatric aspects
 of, **683-691**
 in women, diabetes mellitus, 687-689
 glucocorticoid, 686-687
 hypothalamic-pituitary, 683-685
 hypothalamic-pituitary-adrenal
 axis, 686
 hypothalamic-pituitary-thyroid
 axis, 685-686
 parathyroid, 689
 psychiatric aspects of, **683-691**
- Enteric nervous system (ENS), 733
- Environment, genetic susceptibility and,
 in schizophrenia, 5
- Essential polyunsaturated fatty acids
 (EPUFAs), antipsychotic medication
 and, 86
 in schizophrenia, in augmentation of
 antipsychotic therapy, 97
 brain phospholipids in,
 functional organization of,
 87-89
 sources and metabolic
 pathways of, 88, 90
 membrane phospholipids in,
 breakdown of, 91-92
 metabolism of, 90-91
 antipsychotic
 treatment effects
 on, 92-93
 dysregulation of,
 94-97
 and neurodevelopment, 93
 and signal transduction,
 93-94
 synthesis of, 90-91
 supplementation of, 94-96
 with antioxidants, 96
- Estradiol, in menopause, 564, 566
- Estrogen, in chronic episodic disorders, 727
 premenstrual dysphoric disorder and,
 532-533
 in sexual function, 674-676
 withdrawal of, panic disorder and, 636
- Estrogen replacement therapy (ERT),
 antidepressant response and,
 exogenous estrogen and, 590
 in menopause, for cognition
 enhancement, 572-573
 for depression, 572
 for hot flushes, 567-568
 with sleep disturbance, 570
 for quality of life enhancement,
 574
- Event-related brain potentials (ERBPs),
 response predictor to antidepressants,
 359
- Event-related potentials (ERPs). See also
 *Loudness dependence of
 auditory-evoked potential (LDAEP)*
 response to pharmacotherapy and, in
 obsessive-compulsive disorder,
 427
- Evidence, transfer into clinical practice,
 213-214
- Evidence-based medicine (EBM), finding
 and evaluating evidence in,
 821-831, 826-827
 clinical vignette of multi-problem
 assessment and multi-modal
 treatment, 822-834
 literature search in, 827
 question formulation in, 824
 for interventions, 825-826
 for outcomes, 826
 patient's population and,
 825
 finding the evidence and evaluating
 evidence in, computerized
 searches, 827
 consultation of primary sources,
 829-830
 evidence-based practices and,
 827-828
 systematic reviews in, 828-829
 use of evidence, 830
 computer-based decision
 support systems, 830
 mental health care and, clinical
 expertise and, 816-817
 consumer and, 816
 informed shared decision-making
 and, 816-817
 policy level and, 817-818
 principles in, 814
 risk and adjusted risk, 816

- state and federal agencies and, 815
 - principles of
 - expand clinical expertise, 812-813
 - in implementation of evidence-based practices, 817
 - incorporated patient preferences, 812
 - individualize evidence, 811-812
 - in mental health care, **811-820**
 - use best available current scientific evidence, 811
 - use in mental health care, 814-815
 - shared decision-making in, 821
- Evidence-based practice. *See* *Evidence-based practice (EBP)*
- Evidence-based practice (EBP), adaptation of existing practice to new challenges, 877
- basis of, self-determination, shared decision making, consumer-centered services in, 920-921
 - challenges and opportunities in, changing practice, 874-875
 - diversity and evidence-based practice, 873-874
 - integration of recovery into evidence-based practice, 872-873
 - policy, advocacy for, 874
 - recognition of consumers and families as allies, 872
- change in, pace of, 1003-1004
- for children, **955-969**. *See also* under *Children*.
- Clinic/community intervention development model in, 964-965
- concept of, 851
- concerns about, administrator, 928-930
- common stakeholder themes, 934-935
 - financial and nonfinancial costs, 934
 - power and control, 934-935
 - skepticism about scientific methods, 934
 - waste as enemy, 935
 - consumer, 921, 924-926
 - evidence-based practice as rigid and discounting clinical experience and consumer choice, 936-937
 - family, 926-927
 - fears and distress with change, 935
 - funding and limitation of resources, 935-936
 - issues of power and control, 937
 - limitations of evidence-based practice, 937
 - misconceptions regarding research and science, 936
 - practitioner, 927-928
 - researcher, 932-934
 - stakeholder, 922-923
- definition of, 827, 920
- disadvantage of, 828
- in evidence-based health care, 1014-1015
- expert consensus guidelines in, 984
- future of in mental health care, **1011-1016**
- change and, 1013-1014
 - dynamic health care systems and, 1015-1016
 - implementation and, 1015
 - principles and, 1012-1013
 - as process, 1014
 - public policy and, 1015
 - training for, 1014
 - values and, 1016
- in geriatric mental health care, **971-990**
- for alcohol abuse, 981
 - for anxiety disorder, 982-983
 - cautions and limitations in, 983-985
 - for dementia with behavioral symptoms, 977-980
 - for depression, 973-977
 - models of service delivery and, 983
 - need for evidence base in, 972-973
 - for schizophrenia, 981-982
- in health care systems, 813-815
- identification and use of, 828
- implementation of, challenge of, 883-884
- consumers and family partners in, **867-881**
 - enactment phase, 887-891
 - funding of, Medicaid in, 890-891
 - in future, 1015
 - literature relevant to, 884-886
 - adaptation of individual models to organizational delivery, 885
 - motivational phase, 886-888
 - multiple interventions in, 885-886
 - pilot programs for, 888-889
 - for practice change, 884-886
 - professional training for, 891-892

Evidence-based (*continued*)

- at program level, 888-893
- staff in, 889-890
- strategies for, **883-897**
- at systems level, 888-892
- work flow in, 890
- mental health services and, quality and accountability in, 900-902
- methodology for determination of, limitation of, 984
- movement forward in, three-track approach to, 877
- principles of, expand clinical expertise, 1003
 - include patients in decision-making, 1013
 - individualize the evidence, 1012-1013
 - use of best available evidence, 1012
- process of, 1014
- public policy and, **899-917**. See also *Policy*.
- quality of care and, in geriatric population, 983
- research partnerships in support of, 877-878
- in schizophrenia, **939-954**. See also under *Schizophrenia*.
- teaching of, outcomes of, 862-863
 - promotion strategies for, 859-862
 - access to search engines, 861
 - anticipation and response to negative attitudes, 860
 - assessment of student competencies in, 862
 - faculty/supervisor mentors in, 860-861
 - imbed evidence-based practice training in curriculum, 861
 - make evidence-based practice relevant and practical, 860
 - mandate through accreditation requirements, 862
- teaching practices identified as evidence-based, 855-857
 - advantages of, 856-857
 - Implementing Evidence-Based Practices for Severe Mental Illness Project and, 855-856
 - Multisystemic Therapy example of, 856
- teaching strategies in, evidence-based, 857-858
 - effects of, 858-859
- teaching the process of, assessment of

- relevance of valid information in, 852, 854
- core competencies in, 852-855
- critical appraisal skills in, 853-854
- electronic searches of literature in, 852-853
- formulation of clinical question in, 852-853
- methods in, 854-855
- training in, **851-865**, 1014
- treatment effectiveness reports and, conflicts of interest bias in, 984-985
- US Surgeon General's 1999 report and, 899-900
- children in, 955

Evidence-based psychiatry, information technology in, **833-850**. See also *Automated self-report*.

- automated self-report assessment systems and, 835-838
- from clinical care to research and, 833-834, 843-844
- clinical computing in psychiatric education, 844-845
- computer-based self-reports, from clinician-administered instruments, 836
- electronic medical record in, 834-835
- from research to clinical care and, 833-834, 842-843
- severity rating scales and, 838-842
- use by psychiatrists, 845

Evidence-based treatment, in schizophrenia, 215-216

- Evoked potentials, lithium response and, 329
- Executive function, in schizophrenia, 28-29, 32
- Exercise, for premenstrual dysphoric disorder, 537
- Exercise and diet, of person with schizophrenia, 127
- Exposure therapy, complex posttraumatic stress disorder and, 770-771
- for posttraumatic stress disorder, 768-769
- Expressed emotion, by family of person with schizophrenia, 199-200, 278
- Extrapyramidal reactions, to typical antipsychotics, 368, 369, 370-371
- Eye movement desensitization and reprogramming (EMDR), for posttraumatic stress disorder, 769

F

- Family. See also *Consumers and families*
as case manager, for ill member in community living, 870
concerns about evidence-based practice, emphasis of clinical trials versus reports of lived experience, 926-927
loss of position as agents of reform, 927
shift in funding away from family-to-family initiatives, 926
maternal depression and, 549-550
women with breast cancer, role and care of, 721
- Family environment, of children and adolescents, with mood disorders, as response predictor, 440-442
treatment selection and, 442
- Family interventions, in schizophrenia, for positive symptom reduction and relapse, 942-943
- Family therapy, in bipolar disorder, 514
in schizophrenia, for relapse reduction, 199-201
- Federal government, mental health service demonstrations and, 912
- Female orgasmic disorder (FOD), 676, 678
- Female sexual arousal disorder (FSAD), 676-678
- Fenfluramine challenge test, response prediction and, 327-328
- Fetus, antidepressant exposure and, neurobehavioral effects of, 555
teratogenesis from, 551-553
bipolar disorder and, 605
maternal depression and, 549
- Fibromyalgia syndrome (FMS), 733
overlap with chronic episodic disorder, 734
- Fluoxetine, in bipolar II disorder, 602
in geriatric depression, 356
in major depressive disorder, response prediction and, PET study, 336
with olanzapine, in break-through depression, 508
during pregnancy, 552, 554-555, 557
in premenstrual dysphoric disorder, 538-539
response prediction study, baseline variables in, 350-351
initial improvement, 351
negative predictors, 351

- response predictors for, methoxyhydroxyphenylglycol, 360
platelet serotonin content, 361
response to, in atypical depression, 355
gender differences in, 588-589
in posttraumatic stress disorder, 420-421
in retarded depression, 357
teratogenesis and, 552-553

Fluphenazine, depot, for relapse prevention, 372

Follicle-stimulating hormone (FSH), in menopause, 564-566

Functional family therapy, evidence-based practice implementation and, 958, 960

Functional imaging, in major depressive disorder, 335
response prediction and, in affective illness, 334-336
with tryptophan depletion, relapse risk and, 336

G

- Gabapentin, in bipolar disorder, 506
in hot flashes, menopausal, 569
- Gama aminobutyric acid (GABA) system, in alcoholism, 383
- Gender, as response predictor, to antidepressants, 357
in cocaine treatment, 393
- Generalized anxiety disorder (GAD), 624-628
comorbidity and, prediction of outcome and, 414
comorbidity rates in, 413-414
depression comorbidity with, 627-628
depressive disorders in, 627
as diagnosis, changes in, 411
DSM definitions of, 412-413
electroencephalographic studies of, 415
female reproductive cycle and, 628
functional imaging studies of, 415
genetic and environmental risk factors for, 414-415
MRI in, in children and adolescents, 415-416
pathophysiology of, 627
premenstrual syndrome and, 628
prevalence of, gender and, 624
in primary care patients, 624-625
prevalences of, 413
primary versus secondary, treatment response in, 626

- Generalized anxiety (*continued*)
psychiatric disorders in, 625
remission prediction in, 414
remission rates for, 626
risk factors for, 413
social phobia and simple phobia with, 625
treatment response in, gender differences in, 627
in women, comorbid psychiatric disorders in, 626-627
pharmacotherapy for, 627-628
- Genetics, association analysis in, 305
in chronic episodic disorders, 735
versus environmental factors, in anxiety disorders, in women, 626-627
and female reproductive cycle, 651-652
in generalized anxiety disorder and depression, 623
linkage analysis in, 304-305
in obsessive-compulsive disorder, 648, 651
in panic disorder, 634-635
in premenstrual dysphoric disorder, 533
of schizophrenia, 41-63
adoption studies in, 45-46
comorbidity and, 115-116
family studies in, 42-43
genetic epidemiology in, 42-46
mode of inheritance in, 46-48
counseling and predictive testing in, 55-56
genetic imprinting and, 48
heterogenous vs. unitary, 47-48
liability/threshold model and, 46-47
phenotype definition in, 54-55
molecular studies in, 48-54
association, 50-52
chromosomal abnormalities, 52-53
linkage, 48-50
trinucleotide repeats, 53-54
twin studies in, 43-45
in separation anxiety, 635
in social anxiety disorder, 643
and vulnerability to schizophrenia, 5
- Genetic testing, of women, for breast cancer, 721-722
- Glucocorticoid, type II receptor levels, as response predictor, 359
- Glucocorticoid disorders, in women, psychiatric symptoms in, 686-687
- Glucose metabolism, with atypical antipsychotics, 169-170
- Gonadotropin-releasing hormone (GnRH) agonists, for premenstrual syndrome/premenstrual dysphoric disorder, 539
- Growth hormone, response to apomorphine challenge, alcoholism relapse and, 382
- Growth hormone (GH), disordered, psychiatric symptoms in, 684
-
- ## H
- Haloperidol, depot, for relapse prevention, 372
- Hamilton Rating Scale for Anxiety (HRS-A), automated version of, 839
- Hamilton Rating Scale for Depression (HRS-D), automated version of, 839
- Hawaii Experiment, EPBs and, adaptation and distillation process in, 961, 965
- Head trauma, violence and, 235
- Heart Estrogen/Progestin Replacement Study (HERS), 697-698
- Hepatitis, risk for, in patient with schizophrenia, 126-127
- HIV infection, risk for, in patient with schizophrenia, 126-127
- Hormonal therapy, in women, for breast cancer, 717-718
- Hormone replacement therapy (HRT), cardiac disease risk and, 697-698
in menopause, 563-564
for depression, 571-572
for hot flashes, 567
in perimenopause and menopause, in bipolar patients, 609-610
- Hostility, cardiac disease and, 698
- Hot flashes, nocturnal, 569-570. See also under *Menopause*
- 5-Hydroxyindoleacetic acid (5-HIAA), response prediction and, to antidepressants, 361
and treatment response, in major depressive disorder, 325
- Hyperlipidemia, antipsychotic medication-related, in schizophrenia, 128-130
with atypical antipsychotics, 170-173
- Hyperprolactinemia, atypical antipsychotic-related, 178-180

- Hyperthyroidism, in women, psychiatric symptoms in, 686
- Hypnotherapy, for complex posttraumatic stress disorder, 771
- Hypoactive sexual desire disorder (HSDD), 676-678
- Hypothalamic-pituitary-adrenal axis disorders, 686
- Hypothalamic-pituitary disorders, in women, 683-685
- Hypothyroidism, in women, psychiatric symptoms in, 685-686

I

- Imipramine, response to, gender differences in, 587-588
- Information processing, in schizophrenia, 29
- Insomnia, menopausal, 569-570
- Interpersonal and social rhythms therapy (IPSRT), in bipolar disorder, 513
- Interpersonal therapy (IPT), for antenatal depression, 550
discontinuation of antidepressant therapy and, 556-57
for panic disorder, 638
- Irritable bowel syndrome (IBS), brain-gut interactions in, 732-733
chronic episodic disorders in, 733
fibromyalgia syndrome and, 734
gender differences in, 732
psychiatric disorders in, 733

J

- Journal clubs, 854-855

K

- Knowledge, transfer into clinical practice, time to, 214

L

- Lactation, lithium and, 608-609
mood stabilizers and, 608
- Lamotrigine, in bipolar disorder, 501-502
prophylactic, 502
rapid cycling, 502
skin rash from, 502-503
in bipolar II disorder, 602
with rapid cycling, 597-598

- serum levels, in nursing infants, 609
teratogenic effects of, 607

- Learning and memory, in schizophrenia, 30-31
- Leuprolide acetate, in premenstrual syndrome/premenstrual dysphoric disorder, 539
- Levo-alpha acetylmethadol (LAAM), for opioid use disorders, 998
- Life event stress, depression and, in women, 784
depressive illness and, 583-584
premenstrual syndrome/premenstrual dysphoric disorder and, 535
- Light therapy, response to, in depression, 358
- Linkage studies, description of, 48-49
in schizophrenia, classic markers in, 49-50
criticisms of, 49
replication to chromosomal regions and, 50
- Lithium, as antidepressant, 506-507
augmentation, in treatment-resistant depression, 465-466
of tricyclics, demographic response predictors and, 357
in bipolar disorder, comparison of paroxetine and imipramine augmentation of, 501
as first-line therapy, 501
gender differences and, 603
in bipolar II disorder, 602
response predictors to, in children and adolescents, 445, 447
response to, in mixed mania, 599
in STAR*D protocol, as augmentation strategy, 481
teratogenic effects of, 606
therapeutic response to, rapid cycling and, 597
in women, effects of, 604
- Lithium toxicity, in nursing infant, 608-609
- Loudness dependence of auditory-evoked potential (LDAEP), antidepressant response studies and, 328-329

M

- Magnetic resonance imaging (MRI), white matter hyperintensities in, treatment response and, in bipolar disorder, 333
in major depressive disorder, 330-332

- Magnetic resonance spectroscopy (MRS), response prediction and, in affective disorders, 333-334
- Magnetic resonance spectroscopy-phosphorus (31P-MRS), response prediction and, in depression, 334
- Magnetic resonance spectroscopy-proton (1H-MRS), response prediction and, in depression, 333-334
- Major depression, automated self-report in, 839
cardiac disease and, 700-701
risk for, gender differences in, 622-623
simple phobia and, 639
in women, with hypopituitarism, 684
- Major depressive disorder (MDD), in alcoholism, response prediction and, 388
characterization of, as chronic and recurrent, 458-459
as common condition, 458
as costly, 459-460
as disabling, 459
in children and adolescents, comorbidity in, 445-446
outcome model in, 435-436
concurrent with generalized anxiety disorder, 414
gender differences in, 581
life event stress and, 584
in panic disorder, 630
pregnancy and, antidepressants in, 547-548
social anxiety disorder and, 642
treatment of, availability of effective options for, 460
long-term, 462
practice guidelines for, 461-462
previously unsuccessful, 460-461
psychotherapy in, 461
symptom remission versus reduction or response in, 460
treatment-resistant, causes of, 463-464
definition of, 462-463
dosing and, 463-464
historical or prospective evidence of, 464
treatment strategies for, augmentation studies, 465-466
combination studies, 465-467
somatic treatments, exclusion in STAR*D study, 469
switching studies, 464-465, 467-469
- Mania, in adolescents, response to lithium and, 445
- mixed, definitions of, 598
gender differences in, 598-599
suicide risk in, 601-602
treatment of, 599
- Manic depression. See *Bipolar disorder (BPD)*
- Maprotiline, response to, gender differences in, 588-589
- Mastectomy, psychological adjustment to, 716-717
- Medication noncompliance, violent behavior and, 234
- Membrane phospholipids. See also *Phospholipids*
in schizophrenia, contents of, 88-89
dysregulation of, **85-102**
EPUFAs in augmentation of antipsychotics, 97
supplementation of combination EPUFAs and antioxidants, 96-97
supplementation of EPUFAs and, 94-96
therapeutic implications, 94-97
essential fatty acids in, 90
fatty acids and, functional organization of, 87-89
source and metabolic pathways of, 87-89
metabolism of, 87-88
neurodevelopment and, 93
signal transduction and, 93-94
- Memory, and learning, in schizophrenia, 30-31
perimenopausal and postmenopausal, 572-573
in schizophrenia, episodic, 32
working, 33
- Menopause, bipolar disorder and, 609-610
depression in, 730-731
endocrine changes in, 564-566
hot flashes and mood disturbance in, **563-580**
characteristics of, 566
definition of, 566
estrogen replacement therapy in, 567-568
hormone replacement therapy in, 567
physiology of, 566-567
sleep disturbance and, 569-570
SSRIs in, 567-569
treatment strategies for, 567-569

- mood disturbance in, 563, 570-572
 - quality of life in, 574
 - sleep in, 569-570
 - cognitive function in, 572-573
 - staging of, 564-565
 - surgical, for premenstrual syndrome/
premenstrual dysphoric disorder,
540
- Menstrual cycle, panic disorder and,
636-637
- Menstrual socialization concept,
premenstrual dysphoric disorder and,
534-535
- Mental disorders/illness, in women,
barriers to treatment and, 788-789
- burden of, 781-782
 - co-occurring mental and medical
conditions, 790-791
 - co-occurring substance abuse
disorders and, 793-794
 - elderly, 790
 - epidemiology and clinical
features of, 782-787
 - ethnic/minority, 791
 - barriers to services for,
791-792
 - evidence-based models of
treatment and referral,
789-790
 - general medical settings and,
788-789
 - pregnant and postpartum, 792
 - services for, 787-794
- Mental health, cardiovascular disease and.
See also *Cardiovascular disease*.
in women, **694-712**
- Mental health care system, antipsychotic
medications and, introduction of,
868-869
- deinstitutionalization and, 868
- Mental health research, women's, public
health context of, **781-799**
- Mental retardation, violence and, 235
- Metabolic syndrome, with atypical
antipsychotics, 173-174
- Metadone, for opioid use disorders, 998
and treatment outcome, 395
- Methoxyhydroxyphenylglycol (MHPG), as
response predictor, to serotonergic
versus noradrenergic medications, 360
- serotonergic versus noradrenergic
medications response and, 360
 - and treatment response, in major
depressive disorder, 325
- Migraine headache, comorbid in bipolar
disorder, gender differences in, 599
- comorbidity in, 726-727
 - fibromyalgia syndrome and, 734
 - in women, comorbid with depression,
731-732
 - reproductive life events and and,
731-732
- Minimum effective dose, in schizophrenia,
220
- Mirtazapine, with SRRIs, in treatment-
resistant depression, 467
- Miscarriage, obsessive-compulsive disorder
and, 652
- Moclobemide, in break-through depression,
511
- Monoamine oxidase inhibitors (MAOIs),
in break-through depression, 510-511
- in complex posttraumatic stress
disorder, 772-773
 - in melancholic depression,
effectiveness of, 355
 - in panic disorder, 637
 - in social anxiety disorder, 644
 - teratogenesis and, 553
- Mood disorders, in children and
adolescents. See also *Affective
disorders; Bipolar disorder (BPD)*.
biologic predictors in,
dexamethasone suppression
test and, 447-448
- electroencephalography,
449
 - sleep polysomnography,
448-449
 - clinical predictors in, 443-447
 - comorbid diagnoses,
445-447
 - illness course, 443
 - symptom presentation,
443-445
 - life stressors and, 442
 - response predictors in, **435-456**
 - severity of illness, family
environment and, 442
 - gender differences and, 547
 - in generalized anxiety disorder, 625
 - psychosocial predictors in, 440-442
 - symptoms, functioning, consumer
perspectives, environmental,
systems model of, 435-436
- Mood stabilizers, in complex posttraumatic
stress disorder, 773
- infant exposure to, through breast
milk, 609
 - teratogenic effects of, 605-606

Mood (continued)

treatment response to, gender differences in, 603

Motivational enhancement therapy/
motivational interviewing, for
substance use disorders, 1000-1001

Multi-dimensional family therapy (MDFT),
for substance use disorders, 1001

Multi-systemic therapy (MST), as
evidence-based practice, 856
for children, 958-959

N

Naltrexone, for alcohol use disorders,
997-998

with ondansetron, response to, in
alcoholism, 389-390

for opioid use disorders, 998-999
for substance abuse-schizophrenia
comorbidity, 123

National Alliance for the Mentally Ill
(NAMI), on criminalization of people
with mental illness, 263-265
development of educational programs
for families and, 871-872

in evidence-based practice promotion
and implementation, advocacy
agenda and, 875
technical assistance, 876

Treatment/Recovery
Information and Advocacy
Database, 876-877

research partnerships with consumers
and families, 877-878
ideal model of, 878

National Alliance for the Mentally ill
(NAMI), research partnerships with
consumers and families and care
providers, 878-879

Neonatal distress syndromes, from
antidepressant exposure, prenatal,
553-554

Neonatal toxicity, antidepressant exposure
and, 554
lithium exposure and, through breast
milk, 608-609

Neurobiology, in depression, 584-585

Neuropathology, of brain, in schizophrenia
and bipolar disorder, 6-8

Neuropeptide Y, in alcoholism, 383

Neuroticism, and outcome, of opioid
detoxification, 396

Neurotransmitters, in sexual function, 675

Nitric oxide, sexual functioning and, 676

O

Obsessive-compulsive disorder
overlap with schizophrenia,
neurocognitive, 11
pathophysiologic, 11
phenomenologic, 10-11
treatment and, 11-12

Obsessive-compulsive disorder (OCD),
CMI studies in, 425-426
comorbidity in, 422
with major depression, 423
genetic component in, 426-427
heterogeneity of, response to treatment
and, 411-412
nonresponse in, to combination
psychopharmacologic and
behavioral treatment, 424
risk factors for, 422, 424
response predictors in, 421-422
response to pharmacotherapy and,
event-related potentials and, 427
functional imaging and, 427-428
response to pharmacotherapy in, 421
age of onset and, 423
comorbidity and, 422
depression and, 423
severity and duration of
symptoms and, 423
tic disorders and, 424

Obsessive-compulsive disorder (OCD),
649-652
automated self-report severity rating
of, 839-840
clinical course of, 646-647
comorbid disorders in, 647, 649
gender differences in, 649-651
genetics and, 648, 651
impairment in functioning and, 647
lifetime prevalence rate for, 646,
649-650
pharmacological treatment for,
648-649
serotonin dysregulation in, 647-648
subgroups of, 646
women and, 646, 649-651

Obsessive-compulsive symptoms, in
schizophrenia, antipsychotics for,
119-120
cognitive behavioral therapy for,
120
detection of, 119
prognostic significance of,
118-119

- Olanzapine, in acute schizophrenia, versus haloperidol, 146
 intramuscular administration of, 149
 versus placebo, 142-143
for aggressive patient with schizophrenia, 249
in bipolar disorder, 505-506
comparison studies with conventional antipsychotics, meta-analysis of, 151
IM, 371
in relapse prevention, in schizophrenia, 373
in schizophrenia, in acute episode, 370
 for cognitive deficits, 34-36
 for cognitive symptoms, 153
 for depressive symptoms, 153
 economic outcomes with, 154-155
 first-episode, 155
 late-onset, 110
 for maintenance treatment, 150
 for negative symptoms, 152
 quality of life with, 155
 refractory to treatment, 156-157
teratogenic effects of, 606-607
triglyceride level increase with, 171-172
- Opioid dependence, pharmacotherapies for, 998-999
 predictors of outcome in, 395-396
- Opioids, endogenous, in alcoholism, 383
- Oral contraceptives, cardiac disease risk and, 697
- Outcome predictors, in substance abuse disorders, 381-409
- Outcomes, in evidence-based medicine, 826
 in evidence-based practice, consumers versus researchers on, 925-926
 teaching of, 862-863
 mediators and moderators of, 436
Schizophrenia Patient Outcomes Research Team (PORT) project, 938, 948-949
- Outpatient commitment, benefits of, 259
 versus coerced community treatment, 258-259
 effectiveness of, 259-261
 judicially mandated, 259
- Oxytocin, sexual functioning and, 675
- P**
- Panic attacks, lifetime prevalence estimate for, 632
- Panic disorder, age and gender differences in, 632-633
 age of onset in, 629-630
 agoraphobia and, 629-630, 633-634
 bipolar disorder in, 601
 clinical course of, 630-631
 female reproductive cycle and, 635-639
 gender differences in, 638-639
 genetic factors in, 634-635
 lifetime prevalence of, age and gender and, 629
 menstrual cycle and, 635-636
 outcome of, 631
 pathophysiology of, 634
 pharmacotherapy for, 631-632, 637-638
 postpartum period and, 637
 pregnancy and, 636-637
 premenstrual exacerbation and suicidality, 635
 psychiatric disorders in, 601, 630
 in women, with obsessive-compulsive disorder, 650
 risk for comorbid psychiatric disorders, 633
- Paraphrenia*, 103
- Parathyroid disorders, in women, psychiatric symptoms in, 689
- Parent-child interaction treatment, evidence-based practice and, 961
- Parenting, as response predictor, in depression, 361
- Parent management training, for externalizing disorders, in children, 961
- Paroxetine, in break-through depression, 508-509
 comparison with venlafaxine, in break-through depression, 509
 response prediction and, PET findings and, 335
 platelet serotonin content and, 360-361
 response predictors for, prolactin response, 361
- Perimenopause, depression in, 730-731
- Personality, dimensions of, genetically independent, 387
 low persistence, in relapse of detoxified alcoholic, 387-388
 novelty seeking, in relapse of detoxified alcoholic, 387
- Personality disorder, with panic disorder, in women, 633

- Personality disorders, in generalized anxiety disorder, 412-413
methadone maintenance programs and, 396
as outcome predictor, of cocaine dependence, 395-396
posttraumatic stress disorder and, 764
- Personal therapy, with pharmacotherapy, in schizophrenia, 196-197
- Pharmacogenomics, Alzheimer's disease and, 314
case for, 303-305
clinical trials, dopamine receptor genes and clozapine response, 309-310
in psychotic disorders, 308-310
serotonin receptor genes and clozapine response, 311
of drug treatment, 303-321,
ethical and regulatory perspective in, 314-315
gene variants and pathophysiology of schizophrenia, 311-312
in individual drug response, 304
in pharmacology and pharmacokinetics, 304
process of, candidate genes and polymorphisms in, 306-307
drug response phenotype in, 305-306
functional gene variant in, 307
sequential elements in, 306
summary of, 307-308
- Pharmacotherapy, in schizophrenia, adverse effects of, 165-190
new and evolving, 141-163
synergy with psychosocial therapies, 191-211
- Phenelzine, versus imipramine, in atypical depression, 355
- Phenotype, in schizophrenia
- Pheochromocytoma, psychiatric symptoms in, 687
- Phobia(s), childhood experiences and, 645
simple, 639
social phobia, 625
sudden cardiac death and, 701
- Phospholipids. See also *Membrane phospholipids*
in schizophrenia, altered synthesis of, EPUFAs in, 90-91
breakdown of, 91
by free radicals, 92
by phospholipases, 91-92
metabolism of, 93
antipsychotic treatment effects on, 92-93
- Phosphorus magnetic resonance spectroscopy (31P-MRS), response prediction and, in depression, 334
- Policy, evidence-based practice and, future of, 1015
implementation initiatives for, infrastructure to support systemic change and, 903
national, 902-903
research base deficiency for mental health treatments and services, 901
state, 902
overcoming systemic barriers to, building science base, 904
ensuring delivery of state-of-the-art treatments, 905-906
ensuring supply of evidence-based practice services and providers, 905
facilitating entry into treatment, 906
improving public awareness of effective treatments, 904-905
overcoming stigma in, 904
reducing financial barriers to treatment, 906-907
tailoring treatment to age, sex, race, culture, 906
recommendations, block grant use and, 916
creation of national infrastructure for leadership, 909-910
in demonstration programs, 911-912
development of quality improvement programs linked to evidence-based practice practices, 908-909
expansion of consumer and family partnerships, 908-909
in funding of, 912-915
modification of Medicaid, 916
at national leadership level, 907-911
revival of national multidisciplinary mental health professional training program, 910-911

- Policy maker, concerns about
evidence-based practice, lawmaker
motivation by anecdote and data,
931-932
 payment for practices outside
 typical benefit structures,
 930
 pressure for conservatism versus
 risk of new initiatives, 931
 pressure to fund vested interests,
 930-931
- Positron emission tomography (PET),
response prediction and, in depression,
334-334
 in major depressive disorder, 335,
 336
 of rostral anterior cingulate cortex,
 response to depression and, 362
- Positron emission tomography with
fluorodeoxyglucose (FDG-PET),
response prediction and, in
obsessive-compulsive disorder, 428
- Postpartum depression, definition of, 729
depression during pregnancy and, 550
pathophysiology of, 730
- Postpartum period, depression in, 550,
607-608, 729-730, 785
 obsessive-compulsive disorder in,
 onset of, 652
 panic disorder and, 637
 psychosis in, bipolar disorder-related,
 608
- Posttraumatic stress disorder (PTSD),
652-658. See also *Complex
posttraumatic stress disorder*
biological alterations in, gender
differences in, 657
in caregiver, of person with
schizophrenia, 283-284
causes of, 652-653
comorbidity in, 764-766
 risk for, 653
course of, 763-764
definition of, 761
DSM-IV definition of, 418
functional impairment in, 765-766
gender differences in, 762-764
lifetime prevalence of, 418
lifetime prevalence rate for, 652
natural course of, 419-420
pathophysiology of, 653-654
preexisting and peritraumatic factors
in, 653
response predictors in, 420-421
response to pharmacotherapy in,
severity of symptoms and, 419
variables in, 419
response to treatment, variables in, 420
risk factors for, 762-763
SSRIs for, 654
 treatment response to, 657-658
trauma exposure and, prevalence of,
761-762
treatment of, 767-768
 models of, 768-769
 results of, 769-770
 for women, 768
in women, 652-657, 762-764, 786
 combat exposure and, 657-658
 comorbid conditions in, 655
 risk for, 624
- Practitioner, concerns about evidence-based
practice, challenge to professional
autonomy and clinical judgment, 928
 lack of time and support for
 learning new skills, 927
 limitation of research finding
 relevance to practice, 927
 today's best practices may be
 discredited tomorrow, 928
- Pregnancy, bipolar disorder and,
discontinuation of medication in,
605, 607
 treatment of, 605-607
obsessive-compulsive disorder and,
onset of, 652
panic disorder and, 636-637
psychiatric disorders during,
pharmacotherapy and, 548
- Premenstrual dysphoric disorder (PMDD),
529-546
in bipolar disorder, treatment of, 605
definition of, 529
demographic predictors of, 534
diagnosis of, 530-531
DSM-IV criteria for, 530
etiology of, 532-536
genetic risk for, 533
hormones and, 532-533
life stress and, 535
prevalence of, 531
risk factors for, 533-536
serotonin and, 533
sexual abuse and, 535-536
sociocultural factors and, 534-535
treatment of, dietary supplements in,
537-538
 group support in, 538
 healthy lifestyle in, 536-537
 manipulation of menstruation
 in, 539-540
 psychotherapy in, 538
 SSRIs in, 538-539
 surgical menopause for, 540
- Premenstrual dysphoric disorder
(PMD), defined, 529

- Premenstrual (continued)**
depressive disorders in, comorbid with chronic episodic disorders, 729
- Premenstrual syndrome (PMS), 529-530**
defined, 529
- Privacy, violation of, and pharmacogenomics, 315**
- Progesterone, premenstrual dysphoric disorder and, 522**
- Prolactin, disordered, psychiatric symptoms in, 685**
response to haloperidol challenge, in alcoholism relapse and, 382
response to tryptophan or fenfluramine, selective serotonin reuptake inhibitor response prediction, 361
in sexual function, 675
- Prolactin challenge, response to selective serotonin reuptake inhibitors and, 328**
- Protein kinase C, in alcoholism, 383**
- Proton magnetic resonance spectroscopy (1H-MRS), response prediction and, in depression, 333-334**
- Psychiatrists, use of computers and, 845**
- Psychodynamic therapy, for substance use disorders, 1001**
- Psychosis, during pregnancy, 558**
- Psychosocial disability, in women with bipolar disorder, 601**
- Psychosocial factors, in depression, 584**
- Psychosocial treatment(s), for cocaine dependence, outcome predictors and, 392**
in geriatric population, for alcohol abuse, 981
for dementia, 978-980
for depression, 975-976
for schizophrenia, 982
with pharmacotherapy, in schizophrenia, **191-211**
assertive community training, 206-207
cognitive behavioral therapy, 197-199
cognitive remediation, 203-204
for deficit symptoms, 193
family treatment, 199-201
for noncompliance, 194
personal therapy, 196-197
psychodynamic psychotherapy, 195-196
for relapse prevention, 194-195
social skills training, 193, 201-203
supported employment, 204-206
- Psychotherapy, in bipolar disorder, 514**
with pharmacotherapy, in schizophrenia, 195-196
for premenstrual dysphoric disorder, 538
- Psychotropic medications, breast-feeding and, 608-609**
-
- Q**
- Q-T segment prolongation, with atypical antipsychotics, 175-176**
risk for, management of, 176, 178
- Quality care, in daily practice, knowledge and evidence in, 213-214**
for schizophrenic patients, **213-229**
in acute phase, 216-219
evidence-based treatment in, 215-216
health economy and, 214
in relapse prevention, 219-221
treatment durations in, 221-222
- Quality improvement, programs linked to evidence-based practice practices, policy and, 908-909**
- Quality management, 223-224**
in psychiatry, 223-224
Psychiatry Quality Measurement program in, 224-226
benefits of, 226-227
data for, 225-226
flexibility of, 226
- Quality of care, evidence-based practice and, in geriatric population, 983**
- Quality of life, in menopause, estrogen replacement therapy for, 574**
- Quetiapine, in acute schizophrenia, versus conventional antipsychotics, 147**
versus haloperidol, 146
versus placebo, 142-143
adverse effects with, Q-T segment prolongation, 177-178
for aggressive patient with schizophrenia, 249-250
comparison studies with conventional antipsychotics, meta-analysis of, 151
comparison with haloperidol, in acute psychotic episodes, 373

comparison with risperidone or
 olanzapine, in schizophrenia, 370
 in schizophrenia, for cognitive deficits,
 34-36
 for cognitive symptoms, 153
 for depressive symptoms, 154
 late-onset, 110-111
 refractory to treatment, 157-158

R

Radiation therapy, for breast cancer in
 women, depressive symptoms with,
 717

Rapid cycling, in bipolar disorder, gender
 differences in, 596-598
 response to treatment and,
 predictor of, 597-598

Rapid eye movement (REM) sleep, in
 alcoholism, 384

Relaxation therapy, for premenstrual
 dysphoric disorder, 538

Reproductive hormones, in women,
 cardiac disease and, 697-698
 depression and, 532-533

Researcher, concerns about evidence-based
 practice, ambiguities in establishing a
 hierarchy of evidence, 933
 based on out-of-date research,
 932-933
 gaps in research base, 932
 generalizability of evidence, 933
 stifling innovation and new
 research, 932

Response prediction, in affective illness,
 324-338. See also *Affective illness*.
 in anxiety disorders, 411-433. See also
 Anxiety disorder(s).
 in bipolar disorder, 438-442. See also
 Bipolar disorder (BPD).
 in depression, 345-352, 353-365. See
 also *under Depression*.
 fluoxetine study, 350-351
 methodologic issues in, definitions of
 response in, variability of, 347
 differences between patient
 subpopulations and, 347
 spontaneous remission and, 347
 predictor in, clinical meaning of,
 345-346
 ideal, 346-347
 reported, 350
 use of, 349-350
 prognostic stratification and, 346
 search for, goals of, 323-324
 statistical issues in, 347

D-type score, 349
 ease of interpretation, 348-349
 generalizability of findings, 348
 type II error problem, 348

Restraint, of hostile psychotic patient, 242
 best practices for, 243
 federal directions and standards
 for, 244

Right to refuse treatment. See also
 Treatment refusal
 history of, 253

Risperidone, in acute schizophrenia,
 versus amisulpride, 148-149
 versus olanzapine, 148

Risperidone, in acute schizophrenia, versus
 conventional antipsychotics, 147
 versus haloperidol, 145-146
 versus placebo, 142
 adverse effects with,
 hyperprolactinemia, 178-179
 Q-T segment prolongation, 177
 for aggressive patient with
 schizophrenia, 248-249
 comparison studies with conventional
 antipsychotics, meta-analysis of,
 150-151
 comparison with fluphenazine
 decanoate or haloperidol
 decanoate, for cost effectiveness,
 375
 comparison with olanzapine, in
 schizophrenia, 369-370
 hyperprolactinemia with, 603-604
 in schizophrenia, for cognitive deficits,
 34-36
 for cognitive symptoms, 152-153
 for depressive symptoms, 153
 first-episode, 155
 for hostility, 154
 late-onset, 109-110
 for maintenance treatment, 149
 for negative symptoms, 152
 refractory to treatment, 155-158
 versus typical antipsychotics, in
 relapse reduction, in
 schizophrenia, 372-373

Role conflict, women and, 748-749

Role overload, women and, 749
 coping strategies for, 749-750

Role strain, women and, 749
 coping strategies for, 749-750

S

Schizoaffective disorder, familial
 transmission of, 5

Schizoaffective (*continued*)

- as overlap between schizophrenia and bipolar disorder, 10

Schizophrenia

- acute phase, antipsychotics in, 216-217

- augmentation of, 218-219
 - nonresponse and options for, 217-218
 - switching of, 218

- combination therapy in comorbidity, 219

- quality care in, 216-219

- acute psychotic episodes in, atypical antipsychotics for, 369-370

- adverse drug effects in, 165-190

- aggression in, pharmacologic management of, 242-251

- adjunctive agents in, 245, 250-251

- atypical antipsychotics, 247-250

- depot preparations, 247
 - drug choice for, 245-246

- Expert Consensus

- Guidelines 1999 for, 242-245

- typical antipsychotics, 246-247

- ancillary symptoms in, medications for, 945-946

- psychosocial treatments for, 946

- antipsychotics in, dosage of, 217

- selection of, 216-217

- atypical antipsychotics in, 142-158

- acute symptoms, comparisons of, 148-149

- versus conventional antipsychotics, 145, 147

- versus haldol, 145-147

- intramuscular

- administration, 149

- versus placebo, 142-144

- for acute symptoms, 142-149

- for cognitive symptoms, 152-153

- for depressive symptoms, 153-154

- for excitement or hostility, 154

- in first-episode, 155

- in maintenance treatment, 149-150

- meta-analyses of random-controlled trials of, 150-151

- for negative symptoms, 152

- pharmacoeconomic studies of, 154

- quality of life and, 155

- in refractory schizophrenia, 155-158

- boundaries of, 1-24

- care pathways in, early intervention services, 76-77

- illness recognition in, 75-76

- cognitive function in, 25-40

- cognitive impairments in, medications for, 947

- comorbidity in, 115-139

- medical, 125-130

- antipsychotic medication side effects, 127

- hyperprolactinemia, 128

- lifestyle factors in, 125-127

- weight gain, diabetes,

- hyperlipidemia in, 128-130

- psychiatric, 116-124

- comparison with bipolar disorder, 2-10

- comparison with obsessive-compulsive disorder, 1, 10-12, 14

- current practices in, evidence about, 948-949

- dopamine hypothesis of, clozapine and, 367, 368

- early intervention in, 65-83

- drive for, 66

- early detection and, 74

- issues in, appropriate treatment, 72-73

- assessment of effectiveness, 74

- false-positive identification rate, 74-75

- physical and emotional side effects, 74

- outcome and duration of

- untreated psychosis, 66-67

- evidence for and against, 67-69

- preventive, 69-70

- prodromal detection and, 70

- studies of, 70-72

- early-onset, comparison with

- late-onset, 103-104

- comparison with midlife-onset, 104

- conventional neuroleptics in, 107-108

- evidence-based treatment of, ancillary symptoms and, 945-946

- cognitive impairments and, 947

- functional impairments and, 947-948

- future research in, 949-950

- indicators for, 939-940

- negative symptoms and, 944-945

- positive symptoms and relapse and, 940-944

- functional impairments in,
 - medications for, 947-948
 - skills training for, 948
 - supported employment for, 948
 - genetics of, **41-63**
 - gene variants and pathophysiology of, 311-312
 - in geriatric mental health care, 981-982
 - historical perspective on, 1-3
 - impact on family, 276-277
 - acute and posttraumatic stress disorder and caregiving, 283-284
 - guilt and grieving, 279
 - healing and, 284-290
 - reaction patterns and, adversary, 281
 - bystander, 280-281
 - custodian, 280
 - relationship patterns of siblings, 281-283
 - siblings outcomes, 279
 - stigmatization of family and patient, 277-279
 - intervention in, timing and opportunities for, **65-84**
 - late-onset, **103-113**
 - antipsychotics in, 105-106
 - atypical antipsychotics in, 108-111
 - conventional neuroleptics in, 106-107
 - course of disease in, 104-105
 - early-onset comparison with, 103-104
 - maintenance treatment of, 222
 - atypical antipsychotics in, 372
 - compliance in, 371-372
 - depot fluphenazine and haloperidol in, 372
 - noncompliance in, predictors of, 371
 - membrane phospholipid dysregulation in, **85-102**
 - as metabolic disorder, 85-86
 - negative symptoms in, medications for, 944-945
 - psychosocial treatments for, 944-945
 - negative symptoms of, clozapine for, 368
 - in older persons, treatment of, 981-982
 - pharmacotherapy for, adverse effects of, **165-190**
 - new and evolving, **141-163**
 - with psychosocial therapies, **191-211**
 - positive symptoms and relapse in,
 - assertive community treatment for, 943
 - cognitive behavioral psychotherapy for, 943-944
 - family interventions for, 942-943
 - medications for, 940-942
 - adjunctive psychopharmacological agents, 942
 - psychosocial treatments for, 942-944
 - prevention of progression in, **367-379**
 - atypical versus typical antipsychotics in, **367-379**
 - prodromal syndromes in, risperidone versus preemptive treatment of, 374
 - public health policy and, **273-294**
 - community development and support and, 290
 - family support and, 284-285
 - financial planning, 285-2
 - health services and, 289
 - housing and, 288-289
 - human resources support of family members, 289-290
 - human services policy environment, 286-287
 - intersectoral collaborations and effective interventions, 287-288
 - pharmaceutical accessibility and, 287
 - and planning for future care, urgent need for, 275-276
 - work and, 288
 - quality care and, **213-229**
 - refractory, atypical antipsychotics for, 155-158
 - clozapine in, 192
 - relapse in, maintenance treatment and, 220
 - prevention of, 219-220
 - psychoeducation and, 220-221
 - rates of, 219
 - schizophrenia spectrum disorders and, 1, 12-14
 - stigma and public health policy for, **273-294**
 - symptom domains and treatment phases in, 368-369
 - symptom groupings in, 368
 - violent patient with, **231-272**
 - in women, 786-787
 - risk factors for, 787
 - treatment implications for, 787
- Schizophrenia Patient Outcomes Research Team (PORT) project, 938, 948-949

- Schizophrenia spectrum disorders (SPDs),
1, 12-14
 comparison with schizophrenia,
 genetic linkage in, 12-13
 morphometric similarities in,
 12-13
 schizophreniform disorder and, 13-14
- Schizophrenic spectrum, and schizophrenia,
1-2, 14
- Schizophreniform disorder, and
schizophrenia, 1, 14
 schizophrenia and, 13-14
 schizophrenia spectrum and, 13
- Schizotypal personality, and schizophrenia,
1, 14
- SCID. See *Structured Clinical Interview
for DSM-IV (SCID)*
- SCID Screening Patient Questionnaire
(SSPQ), for automated self-report,
837-838
- Seasonal affective disorder, gender
differences in, 586
- Seclusion, of hostile psychotic patient, 241
 best practices for, 243
 federal directions and standards
 for, 244
- Selective serotonin reuptake inhibitors
(SSRIs), in complex posttraumatic
stress disorder, 772-773
 in generalized anxiety disorder, 627
 in hot flashes, menopausal, 567-569
 in obsessive-compulsive disorder,
 648-649
 in panic disorder, 631, 637-638
 in posttraumatic stress disorder, 654,
 657-658
 during pregnancy, 552, 553, 554, 555,
 557, 558
 in premenstrual dysphoric disorder,
 729
 in social anxiety disorder, 644
 teratogenesis from, 552-553
 withdrawal from, neonatal, 554
- Selective serotonin reuptake inhibitors
(SSRIs), in break-through depression,
508-510
- Self-efficacy, and outcome, of opioid
detoxification, 396
- Self-help groups, as predictor of reduced
cocaine use, 392-393
- Self-reports. See also *Automated self-report
computer-based, development from
structured clinician-administered
instruments, 835*
- Sequenced treatment alternatives to relieve
depression (STAR*D), 457-494
 dissemination of findings in, need for,
 485-487
 generalizability issues, education of
 participants and significant
 others, 473-477
 generalizability issues in, clinician
 adherence, 471-472
 compensation, 474
 concurrent medications,
 nonpsychotropic, 476
 psychotropic, 475-476
 concurrent psychotherapy, 476
 discontinuation guidelines, 475
 duration, dose, symptom, side
 effect assessment, 471
 follow-up, 474
 participant adherence, 472-473
 of participant population, 470
 reminders, 474
 routine versus high-quality
 treatment, 470-471
 study affiliation, 473
 limitations of protocol, 485
 major depressive disorder and,
 457-462, 458-462
 masking in, 484
 outcome assessment issues, domains of
 outcome, 476
 function, 477
 health care utilization and cost,
 478
 participant satisfaction, 478
 quality of life, 477
 side effect burden, 477-478
 symptoms, 476-477
 prediction, of relapse or recurrence,
 485
 of response or remission, 484
 protocol overview, level 1, 479-480
 level 2, 479-481
 level 3, 481
 level 4, 481
 primary objectives, 479-480
 selection of options, 482
 randomization in, equipoise versus
 forced, 482-484
 rationale for, 458-462
 tactical issues in, dose and duration,
 484
 in treatment-resistant depression,
 462-464
 treatment-resistant treatment
 depression and, 462-464
 treatment strategies for, 464-470
- Serotonin, in alcoholism, risk for and
response prediction in, 383
 plasma, fluoxetine response and, 360

- Serotonin (5-HT), in chronic episodic disorders, 727, 732
in neurobiology of cardiac disease, 701-702
in obsessive-compulsive disorder, 647-648
in premenstrual dysphoric disorder, 533
- Sertindole, in acute schizophrenia, versus haloperidol, 147
versus placebo, 143-144
in schizophrenia, for maintenance treatment, 150
- Sertraline, response to, gender differences in, 587-588
- Sertraline (SER), versus fluoxetine, in melancholic depression, 355
in STAR*D protocol, augmentation in, 481
in switching, 480
- Sexual disorder(s), in women, DSM-IV and, 676
female orgasmic disorder, 676, 678
female sexual arousal disorder, 676-678
hypoactive sexual desire disorder, 676
prevalence of, 677-678
- Sexual dysfunction, diagnostic classification of, 673-674
in women, **673-682**
assessment of, 678-679
with diabetes mellitus, 688
hormone therapy for, 680
neurobiology of normal function and, 674-676
pharmacotherapy for, 680
treatment considerations in, 679-680
- Sexual function, peripheral effects on, 675-676
in women, 673-674, **673-682**
neurobiology of, 674-676
- Sexual side effects, of conventional and atypical antipsychotics, 181-182
ejaculatory dysfunction, 182-183
erectile dysfunction, 182-183
fertility and pregnancy, 183-184
gender and, 182
priapism, 183
- Simple phobia, generalized anxiety disorder and, 625
lifetime prevalence rate, 639
psychiatric comorbidity in, 639
situational, 639-640
women and, 640
- Single photon emission computed tomography (SPECT), neurotransmitters on, treatment response correlation with, 336
- Single photon emission computed tomography (SPECT-99mECD), response prediction and, in obsessive-compulsive disorder, 427-428
- Skills training
in schizophrenia, 31-32
assertive community training, 206-207
for functional impairment, 948
motor, 201-202
psychosocial, 201-203
- Sleep, in alcoholism, 384
hot flushes during, nocturnal, 569-570
regulation of, for premenstrual dysphoric disorder, 537
- Sleep polysomnography, as response predictor, in children and adolescents, 448-449
- Smoking, panic disorder and, in women, 633-634
- Smoking cessation, in persons with schizophrenia, 126
relapse and, risk factors for, 397-398
- Social anxiety disorder (SAD), age of onset, 641
agoraphobia with, 644-645
avoidant personality disorder and, 643
comorbid disorders in, 642-643
comorbidity in, 417
depression in, 642-643
diagnostic criteria for, 416
environmental influence in, 417
gender differences in, 640-641, 644-645
genetic predisposition to, 417
genetics and, 643
lifetime prevalence rate for, 640
neurobiology of, 643
pharmacotherapy for, 644
prevalence of, 416-417
public speaking anxiety in, 640-641
subtypes of, 641-642
treatment failure in, patient variables and, 418
types of, 640-641
women and, 644-645
- Social phobia, automated self-report severity rating of, 840
generalized anxiety disorder and, 625

- Social skills training, cognitive remediation model, 201-202
motor skills model, 201-202
with pharmacotherapy, for schizophrenia, 201-203
social problem-solving model, 201, 203
- Sociodemographics, treatment response and, in cocaine dependence, 391
- Socioeconomic factors, as response predictor, to antidepressants, 357-358
- Stage model for behavioral therapy research, evidence-based practice and, for substance use disorders, 994-995
- STAR*D. See *Sequenced treatment alternatives to relieve depression (STAR*D)*
- Stigma, and public health policy, for schizophrenia, 273-294
- Stress, in alcoholism, 386-387
anxiety disorders and, 700
smoking cessation relapse and, 397
workload-related, 751
- Stress inoculation therapy (SIT), for posttraumatic stress disorder, 768
- Structured Clinical Interview for DSM-IV (SCID), 833
ASR versions of, 837-838
- Substance abuse, in schizophrenia, complications from, 120-121
detection of, 121
gender and, 120
neurobiologic theory for, 121
pharmacotherapy for, 122-123
self-medication hypothesis for, 121
violent behavior and, 234
- Substance abuse disorder(s), alcoholism. See *Alcoholism*.
cocaine. See *Cocaine dependence*.
opioids. See *Opioid dependence*.
outcome predictors in, 381-409
tobacco. See *Tobacco dependence*.
- Substance use disorders, in bipolar disorder, 600
in panic disorder, 630
in posttraumatic stress disorder, 764
in schizophrenia, 116
in women, co-occurring mental disorder/illness and, 793-794
- Substance use disorder(s), addiction treatment services for, 1002
evidence-based practice for, 991-1010
behavioral or psychological therapies, 997, 999-1001
effective treatments for, principles of, 1002-1003
hierarchy of evidence models in, 993-996
American Psychological Association, clinical psychology division, 994-995
evidence-based medicine, 994-995
stage model for behavioral therapy research, 994-995
US Food and Drug Administration Center for Evaluation and Research, 994-996
implementation of, 1003-1004
pharmacological therapies, 996-999
from research practices to community settings, 1003-1004
integration of psychotherapy and psychopharmacotherapy, 1001
- Suicidality, in bipolar disorders, 601-602
during pregnancy, 558
in schizophrenia, medications for, 946
in social anxiety disorder, 642-643
- Suicide, attempted, gender differences in, 586
panic disorder and, in women, 633
schizophrenia and, detection of suicidal ideation in, 124
psychoeducation and medication compliance and, 124
psychopharmacologic interventions for, 124
risk factors for, 123-124
- Supported employment, in schizophrenia, 204-206
common elements of, 205
interpersonal placement and, 205-206
versus vocational rehabilitation, 205
- Symptom Driven Diagnostic System for Primary Care (SDDS-PC), 836
- Symptoms, functioning, consumer perspectives, environmental, systems (SFCEs) model, of mood disorders, 435-436
- Systolic blood pressure, positional challenge and, response to tricyclics and, 358

T

- Temperament dimensions, as response predictor, to paroxetine, 361
- Testosterone, premenstrual dysphoric disorder and, 532-533
in sexual function, 674-676
- Thyroid hormone, as augmentation strategy, in STAR*D protocol, 481
in treatment-resistant depression, 466
- Thyroid hormone challenge, treatment response and, 326-327
- Tobacco dependence, treatment outcomes in, severity of dependence and, 396-397
treatment relapse in, risk factors for, 397-398
- Topiramate, in bipolar disorder, 506
- Tranlycypromine, in break-through depression, 511
in STAR*D protocol, combination mirtazapine and venlafaxine, as switch option, 481
as switch option, 481
- Trauma. See also *Posttraumatic stress disorder (PTSD)*
assaultive, posttraumatic stress disorder and, 655-656
childhood, 760-761
exposure to, 761-762
prevalence of, 761-762
posttraumatic stress disorder following, 761-774
resilience and, 766
to women, 759-779
physical and sexual violence, prevalence of, 759-760
risk for, 760
therapeutic principles and, 773-774
- Treatment foster care (TFC), for children, evidence-based practice for, 958-959
- Treatment/Recovery Information and Advocacy Database (TRIAD), characterization of systems of care by state, 876-877
measurement of evidence-based practice implementation in, 876
- Treatment refusal. See also *Right to refuse treatment*
by aggressive patient with schizophrenia, duty to protect, 262-263
liability and documentation of, 261-262

- psychiatric advance directives and, 257-258
- capacity to consent to treatment and, 251-252
- legal models for, incompetence component of commitment procedure, 253-254
rights-driven, 253
treatment-driven, 253
- management of, accommodation, 256
coercion and persuasion in, 256-257
consultation, 256
negotiation, 256
- outpatient commitment, 258-261
- types of, illness-based, 255
physician-patient relationship in, 254-255
religion-based, 255
treatment-based, 255
- Tricyclic antidepressants (TCAs), in complex posttraumatic stress disorder, 772-773
in obsessive-compulsive disorder, 648
in panic disorder, 637
during pregnancy, 552, 554, 555, 557, 558
in pregnancy, doses of, 587
teratogenesis from, 552
withdrawal from, neonatal, 554
- Tricyclics (TCAs), in melancholic depression, effectiveness of, 355
negative response prediction and, 350
response predictors and, 356-357
with selective serotonin reuptake inhibitors, in treatment-resistant depression, 466
- Tryptophan, dietary depletion of, prediction of depression and, 360
- Twelve-step Facilitation Therapy (TSF), for substance use disorders, 1001

U

- US Food and Drug Administration Center for Evaluation and Research, evidence-based practice and, for substance use disorders, 994-996
- US Surgeon General's 1999 Report on Mental Health, evidence-based practice and, for children, 955

V

- Valproate, for aggressive patient with schizophrenia, 250
response to, in children and adolescents, 449
in women, effects of, 604

- Values, evidence-based practice and, 1016
- Velocardiofacial syndrome (VCFS), in
bipolar disorder, 115
relationship to schizophrenia, 53
in schizophrenia, 115
- Venlafaxine, in break-through depression,
510
comparison with SSRIs, in depression,
589-590
in generalized anxiety disorder, 627
during pregnancy, 553
- Victimization, of mentally ill family
member, 283-284
- Violence. See also *Aggression*
advocacy and political efforts to
reduce, 263-265
Crisis Intervention Team model, police
training for, 263, 265
and general population, 232-233
inpatient, 236-237
in mental illness, epidemiology of,
232-236
risk factors for, 233-236
outpatient, 258-261
in patients with schizophrenia. See also
Right to refuse treatment;
Treatment refusal.
forced medication and right to
refuse treatment, 251-263
of psychotic patient, treatment issues
in, 231-272
risk assessment of, in mentally ill
person, 237-239
in schizophrenia, medications for, 946
threat of, 238-239
- Vitamin B₆, for premenstrual dysphoric
disorder, 537
-
- W**
- Weight, in bipolar patients, gender
differences in, 600
- Weight gain, antipsychotic
medication-related, in schizophrenia,
128-130
with atypical antipsychotics, 165-169
in adolescents, 167
predictors of, 167
psychopharmacology of, 167-169
5HT_{2c} antagonism and,
168
leptin in, 168-169
time course of progression in,
166-167
smoking cessation relapse and,
397-398
- Weight gain, diabetes, dyslipidemia triad,
with atypical antipsychotics, 165-173
management of, 173-175
- Weight loss agents, for obesity, atypical
antipsychotic-related, 174-175
- Withdrawal, from antidepressants,
neonatal, 554
- Women, anxiety disorders in. See *Anxiety
disorder(s), in women.*
cardiovascular disease and mental
health in. See under
Cardiovascular disease.
co-occurring mental and substance
abuse disorders in, 793-794
psychosocial aspects of, 741-757
career and family case vignettes,
754-755
coping strategies for role conflict
or overload, 749-750
gender discrimination, 743,
745-746
microinequities, 744-745
midlife to old age, 752-753
motherhood and, 751-752
multiple roles of, enriching and
reinforcing, 750-751
normative life cycle of, current,
742-743
traditional, 741
sandwich generation, 746-747
sexual harassment, 745-746
tokenism, 743-745
workplace institutional strategies
and programs, 750
work problems and work
inhibition, 746
in public health sector, 792-793
research paradigms on women's work,
747-748
competing roles and comparison
with men, 748-749
role expansion from 1975-1984,
748
work-family role convergence,
current, 748, 754
sexual function and dysfunction in. See
under *Sexual dysfunction; Sexual
function.*
- Women's Health Initiative (WHI) study,
563, 698
- Working memory, in schizophrenia, 27-28
-
- Z**
- Ziprasidone, in acute schizophrenia, versus
haloperidol, 146
intramuscular administration of,
149

versus placebo, 143-144
for aggressive patient with
schizophrenia, 250
comparison studies with conventional
antipsychotics, meta-analysis of,
151

comparison with haloperidol, in acute
psychotic episodes, 373
comparison with risperidone or
olanzapine, in schizophrenia,
370
IM formulation of, 371